Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus

Abstract

In this nationwide cohort study of patients with SLE, a protective association was found between the current use of hydroxychloroquine and the occurrence of CV events, but not between remote use of hydroxychloroquine and CV outcomes, highlighting the value of continuous hydroxychloroquine treatment in patients with SLE.